Story perspectives

Immunotherapy Dismantles Tumors in Select Cancer Patients

4/13/2026

Summary

Story summary

The immunotherapy dostarlimab at Memorial Sloan Kettering Cancer Center led to complete tumor disappearance in many patients without surgery.
Knudsen notes that cancer comprises 200 distinct diseases, underscoring the need for tailored treatment strategies.
Only about 5% of tumors are suitable for dostarlimab treatment, prompting ongoing research to broaden its use.
Maureen Sideris, a Memorial Sloan Kettering patient, experienced the therapy's impact firsthand, illustrating progress in cancer care.

1 of 1

Story summary

The immunotherapy dostarlimab at Memorial Sloan Kettering Cancer Center led to complete tumor disappearance in many patients without surgery.
Knudsen notes that cancer comprises 200 distinct diseases, underscoring the need for tailored treatment strategies.
Only about 5% of tumors are suitable for dostarlimab treatment, prompting ongoing research to broaden its use.
Maureen Sideris, a Memorial Sloan Kettering patient, experienced the therapy's impact firsthand, illustrating progress in cancer care.